The online version of this article (doi:10.1186/s12894-015-0031-8) contains supplementary material, which is available to authorized users.
Zalmai Hakimi is employed by Astellas Pharma Global Development and Jameel Nazir is employed by Astellas Pharma Europe Ltd. Lars Heemstra, Anke van Engen, and Cristina Ivanescu are employed by Quintiles Consulting.
All authors contributed to the design of the study, interpretation of the data, critically revised the publication for important intellectual content; and approved the final version for publication. L, A and C collected the data and performed the analyses. All authors have read and approved this manuscript.
Storage symptoms, associated with benign prostatic hyperplasia (BPH), often co-exist with voiding symptoms in men with lower urinary tract symptoms (LUTS). Storage symptoms are likely to be most bothersome, and may not be adequately resolved by treatment with α-blocker or antimuscarinic monotherapy. A recent randomised controlled phase 3 trial (NEPTUNE) demonstrated that a fixed-dose combination (FDC) of solifenacin 6 mg plus an oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg) improved storage symptoms, as well as quality of life, compared with TOCAS alone in men with moderate-to-severe storage symptoms and voiding symptoms. This analysis aimed to assess the cost-effectiveness of a FDC tablet of solifenacin 6 mg plus TOCAS relative to tolterodine plus tamsulosin given concomitantly, from the perspective of the UK National Health Service (NHS).
A Markov model was developed for men aged ≥45 years with LUTS/BPH who have moderate-to-severe storage symptoms and voiding symptoms. The model calculated cost-effectiveness over an analytical time horizon of 1 year and estimated total treatment costs, quality adjusted life years (QALYs) and incremental cost-effectiveness ratio.
The FDC tablet of solifenacin 6 mg plus TOCAS was associated with lower total annual costs (£860 versus £959) and increased QALYs (0.839 versus 0.836), and was therefore dominant compared with tolterodine plus tamsulosin. Time horizon, discontinuation or withdrawal rates, drug cost and utility values were the main drivers of cost-effectiveness. The probability that the FDC tablet of solifenacin 6 mg plus TOCAS is cost-effective was 100% versus tolterodine plus tamsulosin, at a willingness-to-pay threshold of £20,000/QALY gained.
The FDC tablet of solifenacin 6 mg plus TOCAS provides important clinical benefits and is a cost-effective treatment strategy in the UK NHS compared with tolterodine plus tamsulosin for men with both storage and voiding LUTS/BPH.
Gravas S, Bachmann A, Descazeaud A, Drake M, Gratzke C, Madersbacher S, et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Available at: http://uroweb.org/wp-content/uploads/Non-Neurogenic-Male-LUTS_2705.pdf. Last accessed, 20 October 2014.
National Institute for Health and Clinical Excellence (NICE). The management of lower urinary tract symptoms in men (June 2010). Available at: https://www.nice.org.uk/guidance/cg97/resources/cg97-lower-urinary-tract-symptoms-full-guideline3. Last accessed, 20 October 2014.
American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH) 2010. Available at: www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm. Last accessed, 20 October 2014.
Hakimi Z, Johnson M, Nazir J, Blak BT, Odeyemi IAO. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using The Health Improvement Network UK primary care data. Curr Med Res Opin. 2015;31:43–50. CrossRefPubMed
Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A, et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol. 2009;43:307–14. CrossRefPubMed
Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174:1334–8. CrossRefPubMed
van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64:1003–12. CrossRefPubMed
Vesomni SPC. Available from https://www.medicines.org.uk/emc/medicine/28535. Last accessed, 20 October 2014.
Hakimi Z, Mathias SD, Crosby R, Odeyemi IA, Nazir J. Defining clinically meaningful changes for the patient perception of intensity of urgency scale (PPIUS) in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Value Health. 2013;16:PRM150.
Office for National Statistics: UK Interim Life Tables, 1980–82 to 2008–10. Available at: http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Interim+Life+Tables. Last accessed, 20 October 2014.
National Institute for Health and Care Excellence (NICE): Guide to the methods of technology appraisal (June 2008). Available at: http://www.nice.org.uk/article/pmg9/chapter/Foreword. Last accessed, 20 October 2014.
Joint Formulary Committee BNF. British National Formulary (BNF) 66. London: Pharmaceutical Press; 2013.
Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. London: Oxford University Press; 2006.
Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. PubMed
Ismaila A, Walker A, Sayani A, Laroche B, Nickel JC, Posnett J, et al. Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: a Canadian model based on the CombAT trial. Can Urol Assoc J. 2013;7:E393–401. CrossRefPubMedPubMedCentral
Verheggen BG, Lee R, Lieuw On MM, Treur MJ, Botteman MF, Kaplan SA, et al. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. J Med Econ. 2012;15:586–600. CrossRefPubMed
Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care (2013) University of Kent. Compiled by Lesley Curtis. Available at: http://www.pssru.ac.uk/project-pages/unit-costs/2013/#sections. Last accessed, 20 October 2014.
National Health Service (NHS) Reference costs (2012). Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_133578.xls. Last accessed, 20 October 2014.
National Institute for Health and Care Excellence (NICE). Pathways for lower urinary tract symptoms in men. Available at: http://pathways.nice.org.uk/pathways/lower-urinary-tract-symptoms-in-men#content=view-node%3Anodes-drug-treatment. Last accessed, 20 October 2014.
- Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia
Anke van Engen
- BioMed Central
Neu im Fachgebiet Urologie
Meistgelesene Bücher in der Urologie
Mail Icon II